PGS: Can you briefly introduce your company?
Answer: At Acnos Pharma, we act as an extension of your team, delivering dependable, customized support for pre-clinical through Phase I–III trials. Our global sourcing network ensures timely access to commercial drugs, comparators and ancillaries, all managed with precision and care. From cartons to compliance – we ensure your clinical products are securely packaged, correctly labeled and fully trial-ready. Our precision workflows keep your timelines intact and your data reliable.
PGS: Highlight your core services and solutions within the pharma and clinical supply ecosystem?
Answer: We provide global access to comparator drugs, ancillaries and unlicensed medicines through a flexible, quality-driven sourcing model. Whether for single-country studies or complex, multi-region trials – we deliver what you need, when you need it.
- Global sourcing network for full trial coverage
- Tailored procurement for variable lot sizes and expiry needs
- Compliance with all relevant regulatory frameworks
Our sourcing solutions reduce complexity and support trial continuity through efficient, just-in-time delivery and expert logistics management.
PGS: Which markets and regions do you primarily operate in, and how do these geographies influence your service capabilities?
Answer: In a highly regulated and complex environment, country-specific sourcing strategies are critical to the success of international clinical trials. Acnos Pharma combines global reach with local compliance expertise to deliver tailor-made solutions that go far beyond standard supply.
- Risk mitigation through VAT/GST and import duty alignment
- Trusted partner network in over 50 countries
- End-to-end control from sourcing to customs clearance
We ensure that your trial supplies are not only available where needed, but also fully compliant with local requirements – reducing cost, avoiding delays, and keeping your study on track.
PGS: What differentiates your solutions from others in the industry, and how do you bring value to pharma clients, CROs, and CDMOs?
Answer: Our sourcing capabilities differentiate us through a combination of a great manufacturer and supplier network, global reach, precision, and agility to support clinical trials and the possibility to do adhoch labelling for these sourced products in our GMP facility in Aachen, Germany. Below are the key elements that set us apart:
We maintain a broad global network of manufacturers (>150 MAH), wholesalers, and licensed distributors, allowing us to source commercial medications—including comparators, biosimilars, and rescue medications—across multiple geographies. This enables us:
- Short supply chains through access directly from the manufacturer without an intermediate supplier
- Access to hard-to-source or limited-supply products.
- Flexibility to source originator or generic drugs per protocol needs.
- Rapid shift between products in the event of shortages or delays.
We ensure full compliance with country-specific requirements for importation, labeling, and distribution. This includes:
- Management of GMP/GDP-compliant documentation.
- Serialization and batch traceability where required.
Together with our sponsors and partners we can optimize sourcing timelines to minimize waste, expiries and overage depending on the study forecast and current enrollment numbers.
We create sourcing assessments and strategies with built-in contingencies, including:
- Alternative sourcing routes and secondary supplier options.
- Feasibility checks for cold chain, stability, and country-specific shelf-life minimums.
We view sourcing not just as procurement, but as a strategic lever to ensure patient safety across the clinical lifecycle, supply continuity and trial speed.
PGS: What major challenges do you foresee for the pharma and clinical supply chain in the coming years, and how is your organization positioned to support and complement industry needs?
Answer: The coming years will bring unprecedented complexity to the pharmaceutical and clinical supply chain — from increased globalization of studies and evolving regulatory landscapes to limited product availability and growing expectations for speed, transparency, and sustainability. These challenges demand partners who combine compliance and reliability with true agility. At Acnos, we see these developments not as obstacles, but as opportunities to create value for our partners. Our sourcing model is built on a global network of over 150 manufacturers (MAHs), accompanied by wholesalers, and licensed distributors, giving us the ability to access even hard-to-source or limited-supply medications directly from manufacturers or through the open market. This ensures short, efficient supply routes and the flexibility to shift rapidly between products or sourcing strategies when market conditions change. In essence, our global reach, precision, and responsiveness empower sponsors to navigate the evolving clinical landscape with confidence — ensuring that patients receive the right medication, at the right time, anywhere in the world.
PGS: How do you see the future of clinical research, logistics, and pharma operations evolving, and what role does your organization aim to play in shaping this future?
Answer: The future of clinical research and pharmaceutical operations is moving toward a model defined by complexity, connectivity, and agility. As trials become increasingly global, decentralised, and data-driven, supply chains must evolve from being merely compliant and reliable to being strategic, adaptive, and intelligent.
We see several key forces shaping this transformation:
- Decentralised and hybrid trial models are redefining how and where studies are conducted, demanding supply chains that can flexibly reach patients anywhere in the world.
- Sustainability, diversity, and patient-centricity are now core operational expectations rather than optional goals.
- And the need for speed and precision in sourcing — particularly for niche, limited-supply is greater than ever.
At Acnos, we view these shifts as opportunities to create value and resilience for our partners. Our mission is to bridge clinical innovation with operational excellence — ensuring that sponsors can execute complex global trials with full confidence in continuity, compliance, and patient safety. Looking ahead, we aim to play a pivotal role in shaping the future of clinical logistics — combining regulatory rigor with true agility. As the industry embraces decentralisation, digitalisation, and patient-centric research, Acnos will continue to evolve as a trusted partner and innovation driver, ensuring that every patient, in every corner of the world, receives the right medication at the right time. Our vision is to help transform the clinical supply chain into a smart, sustainable, and resilient ecosystem — one that empowers faster, more inclusive, and more reliable clinical research worldwide.
